We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.